Javelin granted European patent for pain medication (Pharmaceutical Business Review)
Javelin granted European patent for pain medication (Pharmaceutical Business Review)
Javelin Pharmaceuticals has received a commercially important patent in the European Union that extends patent protection for its PMI-150 drug candidate into 2023.